Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial
Importance Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …
Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: a …
C Bavishi, A Koulova, S Bangalore… - Catheterization and …, 2016 - Wiley Online Library
Objective To compare the efficacy and safety of dual antiplatelet therapy (DAPT) and triple
therapy (TT, dual antiplatelet plus warfarin) in patients with myocardial infarction (MI) or PCI …
therapy (TT, dual antiplatelet plus warfarin) in patients with myocardial infarction (MI) or PCI …
Manajemen Pemberian Dual Antiplatelet Therapy (DAPT) Pada Pasien Sindrom Koroner Akut Dengan Trombositopenia
ZH Yusa, M Muyasir - Journal of Medical Science, 2023 - rsudza.acehprov.go.id
Abstract Berdasarkan data Riset Kesehatan Dasar (Riskesdas) 2018, prevalensi penyakit
jantung koroner sebagai etiologi utama sindrom koroner akut (SKA) di Indonesia sebesar 1 …
jantung koroner sebagai etiologi utama sindrom koroner akut (SKA) di Indonesia sebesar 1 …
A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making
F Costa, D van Klaveren, A Colombo, F Feres… - American heart …, 2020 - Elsevier
The originally-proposed PRECISE-DAPT score is a 5-item risk score supporting decision-
making for dual antiplatelet therapy 1 duration after PCI. It is unknown if a simplified version …
making for dual antiplatelet therapy 1 duration after PCI. It is unknown if a simplified version …
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: a randomized controlled trial
S Biscaglia, E Tonet, R Pavasini, M Serenelli… - PLoS …, 2017 - journals.plos.org
Background Nuisance bleeding is a major determinant of quality of life and drug
discontinuation in patients on dual antiplatelet therapy (DAPT). However, no randomized …
discontinuation in patients on dual antiplatelet therapy (DAPT). However, no randomized …
Antiplatelet, anticoagulant or both? A tool for pharmacists
A Schmode, M Ackman… - … Journal/Revue des …, 2019 - journals.sagepub.com
Patients with atrial fibrillation (AF) are at an increased risk for thrombosis, and anticoagulant
therapy, preferably with a direct oral anticoagulant (DOAC) for most patients, is indicated for …
therapy, preferably with a direct oral anticoagulant (DOAC) for most patients, is indicated for …
Perceived or calculated bleeding risk and their relation with dual antiplatelet therapy duration in patients undergoing percutaneous coronary intervention
M Ferlini, R Rossini, G Musumeci, N Grieco… - Circulation …, 2019 - Am Heart Assoc
A total of 1054 patients were included; detailed information for risk score calculation was
available in 922 patients, who represent the population of the present analysis. ACS was the …
available in 922 patients, who represent the population of the present analysis. ACS was the …
[HTML][HTML] Adherence to prophylactic dual antiplatelet therapy in patients with acute coronary syndrome–A study conducted at a Saudi university hospital
Z Alrabiah, S Wajid, I Alsulaihim, S Alghadeer… - Saudi Pharmaceutical …, 2020 - Elsevier
Objectives The aim of this study was to evaluate patients' self-reported adherence to dual
antiplatelet therapy (DAPT) and determine the factors associated with premature …
antiplatelet therapy (DAPT) and determine the factors associated with premature …
Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: A retrospective cohort study using a medical information database …
H Yokoi, E Oda, K Kaneko, K Matsubayashi - Cardiovascular Intervention …, 2022 - Springer
In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual
antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we …
antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we …
Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study
N Mihatov, EA Secemsky, DJ Kereiakes… - Cardiovascular …, 2022 - Elsevier
Background Guidelines recommend individualization of dual antiplatelet therapy (DAPT)
duration. Whether to guide decisions based on bleeding risk, ischemic risk or a combination …
duration. Whether to guide decisions based on bleeding risk, ischemic risk or a combination …